• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bellerophon Therapeutics misses EPS estimates in Q3

November 8, 2017 By Sarah Faulkner

Bellerophon TherapeuticsShares in Bellerophon Therapeutics (NSDQ:BLPH) fell slightly today after the company missed EPS expectations on Wall Street with its third quarter results.

The Warren, N.J.-based company posted a net loss of -$7.6 million for the 3 months ended Sept. 30, for bottom-line loss of -81% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -22¢, behind consensus on The Street.

“We continue to achieve important progress in all three of our INOpulse clinical development programs,” CEO Fabian Tenenbaum said in prepared remarks. “In our INOvation-1 Phase III trial for pulmonary arterial hypertension, we now have over 100 sites activated in 17 countries and patient enrollment is progressing as planned. We expect to review both an interim analysis and top-line results from this trial in 2018.

“We are especially encouraged with the recently announced positive top-line Phase II data in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). These results further support the potentially unique role that INOpulse’s targeted vasodilation could have in becoming the first therapy approved for patients suffering from pulmonary hypertension associated with lung diseases, such as PH-COPD and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In order to support the continued development of our robust pipeline, we recently completed a private placement that raised aggregate gross proceeds of approximately $23.4 million, which will allow the company to reach multiple key clinical milestones in our ongoing and planned clinical trials.”

BLPH shares were trading at $1.36 apiece today in morning activity, down -1.2%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Respiratory, Wall Street Beat Tagged With: Bellerophon Therapeutics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS